BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission. Risk Anal 2013;33:544-605. [PMID: 22804479 DOI: 10.1111/j.1539-6924.2012.01864.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Chumakov K, Ehrenfeld E, Agol VI, Wimmer E. Polio eradication at the crossroads. Lancet Glob Health 2021;9:e1172-5. [PMID: 34118192 DOI: 10.1016/S2214-109X(21)00205-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pan WK, Seidman JC, Ali A, Hoest C, Mason C, Mondal D, Knobler SL, Bessong P; MAL-ED Network Investigators. Oral polio vaccine response in the MAL-ED birth cohort study: Considerations for polio eradication strategies. Vaccine 2019;37:352-65. [PMID: 30442479 DOI: 10.1016/j.vaccine.2018.05.080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Henquell C, Mirand A, Richter J, Schuffenecker I, Böttiger B, Diedrich S, Terletskaia-Ladwig E, Christodoulou C, Peigue-Lafeuille H, Bailly JL. Phylogenetic patterns of human coxsackievirus B5 arise from population dynamics between two genogroups and reveal evolutionary factors of molecular adaptation and transmission. J Virol 2013;87:12249-59. [PMID: 24006446 DOI: 10.1128/JVI.02075-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
4 Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. J Infect Dis 2014;210 Suppl 1:S398-411. [PMID: 25316861 DOI: 10.1093/infdis/jit844] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
5 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. BMC Infect Dis 2015;15:389. [PMID: 26404632 DOI: 10.1186/s12879-015-1112-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
6 Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014;210 Suppl 1:S485-97. [PMID: 25316871 DOI: 10.1093/infdis/jit838] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
7 Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. BMC Infect Dis 2016;16:237. [PMID: 27246198 DOI: 10.1186/s12879-016-1537-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
8 McCarthy KA, Chabot-Couture G, Famulare M, Lyons HM, Mercer LD. The risk of type 2 oral polio vaccine use in post-cessation outbreak response. BMC Med 2017;15:175. [PMID: 28974220 DOI: 10.1186/s12916-017-0937-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
9 Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiol Infect 2017;145:217-26. [PMID: 27760579 DOI: 10.1017/S0950268816002302] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
10 Duintjer Tebbens RJ, Thompson KM. Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan. Risk Anal 2019;39:389-401. [PMID: 30239026 DOI: 10.1111/risa.13194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
11 Tebbens RJD, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. Syst Dyn Rev 2018;34:78-120. [PMID: 34552305 DOI: 10.1002/sdr.1589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. J Infect Dis 2014;210 Suppl 1:S424-33. [PMID: 25316864 DOI: 10.1093/infdis/jit843] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
13 Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. Lancet 2014;384:1480-2. [PMID: 25018123 DOI: 10.1016/S0140-6736(14)60983-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
14 Iqbal S, Shi J, Seib K, Lewis P, Moro PL, Woo EJ, Shimabukuro T, Orenstein WA. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12. Lancet Infect Dis 2015;15:1175-82. [PMID: 26289956 DOI: 10.1016/S1473-3099(15)00059-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Rev Vaccines 2020;19:661-86. [PMID: 32741232 DOI: 10.1080/14760584.2020.1791093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
16 Famulare M, Selinger C, McCarthy KA, Eckhoff PA, Chabot-Couture G. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine. PLoS Biol 2018;16:e2002468. [PMID: 29702638 DOI: 10.1371/journal.pbio.2002468] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. J Infect Dis 2014;210 Suppl 1:S475-84. [PMID: 25316870 DOI: 10.1093/infdis/jit845] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
18 Zhao T, Li J, Shi H, Ye H, Ma R, Fu Y, Liu X, Li G, Yang X, Zhao Z, Yang J. Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine. Hum Vaccin Immunother 2021;:1-8. [PMID: 33848232 DOI: 10.1080/21645515.2021.1911213] [Reference Citation Analysis]
19 Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis 2016;16:137. [PMID: 27009272 DOI: 10.1186/s12879-016-1465-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
20 Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Anal 2021;41:329-48. [PMID: 33174263 DOI: 10.1111/risa.13622] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
21 Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan. Risk Anal 2019;39:402-13. [PMID: 30296340 DOI: 10.1111/risa.13214] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
22 Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC Infect Dis 2016;16:231. [PMID: 27230071 DOI: 10.1186/s12879-016-1536-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
23 Giri S, Rajan AK, Kumar N, Dhanapal P, Venkatesan J, Iturriza-Gomara M, Taniuchi M, John J, Abraham AM, Kang G. Comparison of culture, single and multiplex real-time PCR for detection of Sabin poliovirus shedding in recently vaccinated Indian children. J Med Virol 2017;89:1485-8. [PMID: 28213965 DOI: 10.1002/jmv.24793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
24 Duintjer Tebbens RJ, Thompson KM. Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use. MDM Policy Pract 2017;2:2381468317697002. [PMID: 30288417 DOI: 10.1177/2381468317697002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
25 Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013;33:516-43. [PMID: 23461599 DOI: 10.1111/risa.12019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 5.5] [Reference Citation Analysis]
26 Ferreyra-Reyes L, Cruz-Hervert LP, Troy SB, Huang C, Sarnquist C, Delgado-Sánchez G, Canizales-Quintero S, Holubar M, Ferreira-Guerrero E, Montero-Campos R, Rodríguez-Álvarez M, Mongua-Rodriguez N, Maldonado Y, García-García L. Assessing the individual risk of fecal poliovirus shedding among vaccinated and non-vaccinated subjects following national health weeks in Mexico. PLoS One 2017;12:e0185594. [PMID: 29023555 DOI: 10.1371/journal.pone.0185594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. BMC Infect Dis 2014;14:45. [PMID: 24472313 DOI: 10.1186/1471-2334-14-45] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
28 Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013;33:680-702. [PMID: 23470192 DOI: 10.1111/risa.12022] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
29 Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, Rüttimann R, Modlin JF, Gast C. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine 2017;35:7283-91. [PMID: 29150209 DOI: 10.1016/j.vaccine.2017.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis 2015;211:1800-12. [PMID: 25505296 DOI: 10.1093/infdis/jiu674] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
31 Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis 2015;15:379. [PMID: 26382043 DOI: 10.1186/s12879-015-1115-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
32 Behrend MR, Hu H, Nigmatulina KR, Eckhoff P. A quantitative survey of the literature on poliovirus infection and immunity. Int J Infect Dis 2014;18:4-13. [PMID: 24246740 DOI: 10.1016/j.ijid.2013.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
33 Taniuchi M, Famulare M, Zaman K, Uddin MJ, Upfill-Brown AM, Ahmed T, Saha P, Haque R, Bandyopadhyay AS, Modlin JF, Platts-Mills JA, Houpt ER, Yunus M, Petri WA Jr. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study. Lancet Infect Dis 2017;17:1069-79. [PMID: 28693854 DOI: 10.1016/S1473-3099(17)30358-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
34 Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. Risk Anal 2021;41:248-65. [PMID: 31960533 DOI: 10.1111/risa.13447] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
35 Bencskó G, Ferenci T. Effective case/infection ratio of poliomyelitis in vaccinated populations. Epidemiol Infect 2016;144:1933-42. [PMID: 26830060 DOI: 10.1017/S0950268816000078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria. PLoS One 2015;10:e0130123. [PMID: 26068928 DOI: 10.1371/journal.pone.0130123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
37 Steil BP, Jorquera P, Westdijk J, Bakker WA, Johnston RE, Barro M. A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 2014;32:558-63. [PMID: 24333345 DOI: 10.1016/j.vaccine.2013.11.101] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
38 Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. BMC Infect Dis 2015;15:66. [PMID: 25886823 DOI: 10.1186/s12879-015-0791-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
39 Mach O, Verma H, Khandait DW, Sutter RW, O'Connor PM, Pallansch MA, Cochi SL, Linkins RW, Chu SY, Wolff C, Jafari HS. Prevalence of asymptomatic poliovirus infection in older children and adults in northern India: analysis of contact and enhanced community surveillance, 2009. J Infect Dis 2014;210 Suppl 1:S252-8. [PMID: 25316843 DOI: 10.1093/infdis/jit234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Koopman JS, Henry CJ, Park JH, Eisenberg MC, Ionides EL, Eisenberg JN. Dynamics affecting the risk of silent circulation when oral polio vaccination is stopped. Epidemics 2017;20:21-36. [PMID: 28283373 DOI: 10.1016/j.epidem.2017.02.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
41 Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect 2019;147:e295. [PMID: 31647050 DOI: 10.1017/S095026881900181X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
42 Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. Vaccine 2015;33:1568-77. [PMID: 25701673 DOI: 10.1016/j.vaccine.2015.02.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
43 Eichner M, Brockmann SO. Polio emergence in Syria and Israel endangers Europe. Lancet 2013;382:1777. [PMID: 24211043 DOI: 10.1016/S0140-6736(13)62220-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
44 Kalkowska DA, Thompson KM. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029. Risk Anal 2021;41:364-75. [PMID: 33590519 DOI: 10.1111/risa.13664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. Risk Anal 2013;33:505-15. [PMID: 23550939 DOI: 10.1111/risa.12030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
46 Koopmans M. Surveillance strategy for early detection of unusual infectious disease events. Curr Opin Virol 2013;3:185-91. [PMID: 23612329 DOI: 10.1016/j.coviro.2013.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
47 Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. BMC Infect Dis 2015;15:374. [PMID: 26381878 DOI: 10.1186/s12879-015-1113-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
48 Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Another look at silent circulation of poliovirus in small populations. Infect Dis Model 2018;3:107-17. [PMID: 30839913 DOI: 10.1016/j.idm.2018.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infect Dis 2018;18:165. [PMID: 29631539 DOI: 10.1186/s12879-018-3074-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
50 Thompson KM, Kalkowska DA. Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Anal 2021;41:349-63. [PMID: 32645244 DOI: 10.1111/risa.13557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
51 Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines 2018;17:739-51. [PMID: 30056767 DOI: 10.1080/14760584.2018.1506333] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
52 Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. Future Microbiology 2016;11:1549-61. [DOI: 10.2217/fmb-2016-0126] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
53 Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. Expert Rev Vaccines 2014;13:221-34. [PMID: 24308581 DOI: 10.1586/14760584.2014.864563] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
54 Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. J Vaccines Vaccin 2016;7:340. [PMID: 28690915 DOI: 10.4172/2157-7560.1000340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 0.2] [Reference Citation Analysis]
55 Dénes A, Székely L. Global dynamics of a mathematical model for the possible re-emergence of polio. Math Biosci 2017;293:64-74. [PMID: 28859911 DOI: 10.1016/j.mbs.2017.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791-808. [PMID: 25824845 DOI: 10.2217/fmb.15.19] [Cited by in Crossref: 115] [Cited by in F6Publishing: 101] [Article Influence: 19.2] [Reference Citation Analysis]
57 Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. BMC Infect Dis 2015;15:376. [PMID: 26382234 DOI: 10.1186/s12879-015-1116-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
58 Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014;210 Suppl 1:S412-23. [PMID: 25316863 DOI: 10.1093/infdis/jit834] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
59 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Din M, Ali H, Khan M, Waris A, Ullah S, Kashif M, Rahman S, Ali M. Impact of COVID-19 on polio vaccination in Pakistan: a concise overview. Rev Med Virol 2021;31:e2190. [PMID: 33176028 DOI: 10.1002/rmv.2190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Bull JJ, Smithson MW, Nuismer SL. Transmissible Viral Vaccines. Trends Microbiol 2018;26:6-15. [PMID: 29033339 DOI: 10.1016/j.tim.2017.09.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
62 Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013;33:647-63. [PMID: 22985171 DOI: 10.1111/j.1539-6924.2012.01891.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
63 Fontana S, Buttinelli G, Fiore S, Mulaomerovic M, Aćimović J, Amato C, Delogu R, Rezza G, Stefanelli P. Acute flaccid paralysis surveillance in bosnia and herzegovina: Recent isolation of two sabin like type 2 poliovirus. J Med Virol 2017;89:1678-81. [PMID: 28390186 DOI: 10.1002/jmv.24827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM. Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems. Food Environ Virol 2017;9:361-82. [PMID: 28687986 DOI: 10.1007/s12560-017-9314-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
65 Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Anal 2018;38:1701-17. [PMID: 29314143 DOI: 10.1111/risa.12962] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
66 Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013;33:606-46. [PMID: 23550968 DOI: 10.1111/risa.12031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
67 Benninger F, Steiner I. CSF in acute and chronic infectious diseases. Handb Clin Neurol 2017;146:187-206. [PMID: 29110770 DOI: 10.1016/B978-0-12-804279-3.00012-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
68 Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, Oberste MS, Gast C, Brickley EB, Asturias EJ, Rüttimann R, Bandyopadhyay AS. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis 2016;16:1377-84. [PMID: 27638357 DOI: 10.1016/S1473-3099(16)30169-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
69 Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. BMC Infect Dis 2015;15:390. [PMID: 26404780 DOI: 10.1186/s12879-015-1114-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
70 Duizer E, Ruijs WL, van der Weijden CP, Timen A. Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017. Euro Surveill 2017;22:30542. [PMID: 28597830 DOI: 10.2807/1560-7917.ES.2017.22.21.30542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
71 Wright PF, Wieland-alter W, Ilyushina NA, Hoen AG, Arita M, Boesch AW, Ackerman ME, van der Avoort H, Steven Oberste M, Pallansch MA, Burton AH, Jaffar MA, Sutter RW. Intestinal Immunity Is a Determinant of Clearance of Poliovirus After Oral Vaccination. The Journal of Infectious Diseases 2014;209:1628-34. [DOI: 10.1093/infdis/jit671] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
72 Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SGF, Cochi SL, Thompson KM. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses: Poliovirus Transmission and Evolution Model. Risk Analysis 2013;33:703-49. [DOI: 10.1111/risa.12044] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 9.4] [Reference Citation Analysis]
73 Houy N. The probability of undetected wild poliovirus circulation: Can we do better? J Theor Biol 2015;382:272-8. [PMID: 26165452 DOI: 10.1016/j.jtbi.2015.06.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
74 Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. Vaccine 2017;35:3823-33. [PMID: 28606811 DOI: 10.1016/j.vaccine.2017.05.090] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]